Romano Federica, Mombasi Precia, Garofalo Franco, Namarvari Nima, Franco Francesco, Defabianis Patrizia, Berta Giovanni Nicolao
Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Via Nizza 230, 10126 Turin, Italy.
Paediatric Rheumatology Unit, Paediatric Department, Rivoli Hospital, Via Rivalta 29, 10098 Rivoli, Italy.
Medicina (Kaunas). 2025 Jun 19;61(6):1115. doi: 10.3390/medicina61061115.
: Despite recent advancements in treatment, children with juvenile idiopathic arthritis (JIA) continue to experience poor health-related quality of life, and data on patient and parent satisfaction with disease management remain limited. Thus, this cross-sectional study aimed to explore the factors influencing parental satisfaction with their child's JIA care, using the juvenile arthritis parent acceptable symptom state (JA-PASS). : Parents of 63 children (43 females and 20 males; mean age 12.2 ± 3.7 years) diagnosed with JIA completed the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). The study analyzed JAMAR responses, along with demographic data, disease duration and activity, and current medication use, to identify clinical factors that influence JA-PASS. : According to the JAMAR, 55.6% of parents expressed satisfaction with their child's current condition. In a multiple regression analysis, significant factors influencing JA-PASS included medication side effects ( = 0.033), current disease activity ( = 0.009), and the psychosocial well-being rating in the JAMAR questionnaire ( = 0.048). : JA-PASS should be integrated into patient assessment protocols, as it provides valuable insight into parents' perceptions of disease progression and effectiveness of therapeutic interventions.
尽管近期在治疗方面取得了进展,但幼年特发性关节炎(JIA)患儿的健康相关生活质量仍然较差,关于患者及其父母对疾病管理满意度的数据仍然有限。因此,这项横断面研究旨在利用幼年关节炎父母可接受症状状态(JA-PASS)来探讨影响父母对其孩子JIA护理满意度的因素。
63名被诊断为JIA的儿童(43名女性和20名男性;平均年龄12.2±3.7岁)的父母完成了幼年关节炎多维评估报告(JAMAR)。该研究分析了JAMAR的回答,以及人口统计学数据、疾病持续时间和活动情况,以及当前的用药情况,以确定影响JA-PASS的临床因素。
根据JAMAR,55.6%的父母对其孩子目前的状况表示满意。在多元回归分析中,影响JA-PASS的重要因素包括药物副作用(P = 0.033)、当前疾病活动(P = 0.009)以及JAMAR问卷中的心理社会幸福感评分(P = 0.048)。
JA-PASS应纳入患者评估方案,因为它能为父母对疾病进展和治疗干预效果的看法提供有价值的见解。